Targeting L‐Selectin Lymphocytes to Deliver Immunosuppressive Drug in Lymph Nodes for Durable Multiple Sclerosis Treatment
Advanced Science · 2023
DOI: 10.1002/advs.202300738 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2023. Verfasst von Yipeng Zhao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510000, China. Hauptthemen laut MEDLINE: Encephalomyelitis, Autoimmune, Experimental, Multiple Sclerosis. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: STI 2030-Major Projects, Chinese Postdoctoral Science Foundation, Natural Science Foundation of Guangdong Province.
Abstract (Originalsprache)
Inflammation induced by autoreactive CD4 + T lymphocytes is a major factor in the pathogenesis of multiple sclerosis (MS). Immunosuppressive drugs, such as FTY720, are subsequently developed to prevent the migration of CD4 + T lymphocytes to the central nervous system (CNS). However, these immunosuppressive drugs have limited accumulation in lymph nodes (LNs), resulting in poor efficacy. Here, this work develops a nanoplatform for delivering immunosuppressive drugs to LNs for durable MS treatment. Human CD47 peptide and L‐selectin targeting aptamer are modified on the nanoparticles encapsulated with FTY720 (clnFTY) for self‐passivation and the targeting of L‐selectin on lymphocytes, a homing receptor for T‐cells entering LNs. Using this natural process, clnFTY nanoparticles efficiently deliver FTY720 to LNs and delay disease progression in experimental autoimmune encephalomyelitis (EAE) mice following a single dose treatment over a 42‐day observational period. Considering the daily dosing requirement of FTY720, this strategy greatly improves its therapeutic efficiency. The ability of clnFTY nanoparticles to target lymphocytes, reduce sphingosine‐1‐phosphate receptor 1 (S1PR1) expression, and suppress inflammatory cytokines release are demonstrated in clinical blood samples from MS patients. Taken together, this study demonstrates that targeted LNs delivery may greatly extend the treatment cycle of immunosuppressive drugs for durable MS treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510000, China.
- CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, 100190, China.
- School of Nanoscience and Engineering, University of Chinese Academy of Sciences, 100049, Beijing, China.
ORCID-Profile: Hai Wang
Förderung
- STI 2030-Major Projects
- Chinese Postdoctoral Science Foundation
- Natural Science Foundation of Guangdong Province
- NSFC
- National Natural Science Foundation of China
Zitieren
APA
Zhao, Y., Zhang, J., Cheng, X., Huang, W., Shen, S., Wu, S., Huang, Y., Nie, G., Wang, H., & Qiu, W. (2023). Targeting L‐Selectin Lymphocytes to Deliver Immunosuppressive Drug in Lymph Nodes for Durable Multiple Sclerosis Treatment. Advanced Science. https://doi.org/10.1002/advs.202300738
Vancouver
Zhao Y, Zhang J, Cheng X, Huang W, Shen S, Wu S, et al. Targeting L‐Selectin Lymphocytes to Deliver Immunosuppressive Drug in Lymph Nodes for Durable Multiple Sclerosis Treatment. Advanced Science. 2023. doi:10.1002/advs.202300738
BibTeX
@article{Zhao2023,
author = {Zhao, Yipeng and Zhang, Jie and Cheng, Xi and Huang, Wenping and Shen, Shishi and Wu, Shilin and Huang, Yiying and Nie, Guangjun and Wang, Hai and Qiu, Wei},
title = {Targeting L‐Selectin Lymphocytes to Deliver Immunosuppressive Drug in Lymph Nodes for Durable Multiple Sclerosis Treatment},
journal = {Advanced Science},
year = {2023},
doi = {10.1002/advs.202300738}
}
EUVIMED